Categories:
ALS Events
ALS News
ALS Research
ALS Spotlight
Commentary
Health News
Kids Care
Living with ALS
PALS Profiles
Passages
Patient Services
Ride for Life News
Ride for Life Website
Stem Cell Research
Support Groups
All Archives
Navigate:
Ride for Life Home
ALS News Center
ALS Events
About Ride for Life
Ride for Life FAQ
Join Ride for Life
Make Donation
Patient Services
Donate-A-Car for ALS
Shop to Stop ALS
ALS Links
ALS Bookstore
ALS Fast Facts
Kids Care
ALS Support Groups
Search:
  FDA Seeks More Information on CytRx's ALS Drug Candidate
Posted July 22, 2005 in ALS Research

Midnight Trader
This content is provided to LexisNexis by Comtex News Network, Inc.
July 21, 2005 Thursday
LENGTH: 176 words
DATELINE: Boston

CytRx Corp. (CYTR) today said the FDA has asked for more information related to CytRX's investigational new drug application for arimoclomol, a drug to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The FDA said the trial has been placed on clinical hold until the information is provided.

  Email a Link
Use this form to send a link to this article to a friend.

Email this entry to:


Your email address:


Message (optional):


 

For our complete database of ALS news and information go to the ALS NewsCenter

Contact us at email@rideforlife.com  |  Powered by Movable Type  |  Designed by new ajenda  |  Site optimized for 800x600 and above resolutions

This website is a service of Ride for Life, Inc., a 501(c)(3) non-profit organization founded by ALS patients, caregivers, and those concerned about people living with ALS.

Disclaimer: All copyrighted information republished on this website remains the property of the original copyright holder.
Ride for Life, Inc. does not claim to own this information and presents it to our visitors in the spirit of fair usage in order to aid those who are living with ALS.

Privacy Statement: Ride for Life, Inc. does not sell, distribute, or share any personal information.